Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558790 · ClinicalTrials.gov registry record · Phase 2
L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02558790: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02558790 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558790, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a 12-week, open-label pilot study to test the effects of MMFS-201-301 on cognition and function in adults with ADHD. Subjects may enter the trial on a stable dose of medication for ADHD, and MMFS-201-301 will be given. Subjects who do not enter on a stable dose of ADHD medication will receive MMFS-201-301 alone.
Interventions
- DRUG L-Threonic Acid Magnesium Salt (L-TAMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558790
The ClinicalTrials.gov registry entry for NCT02558790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-Threonic Acid Magnesium Salt (L-TAMS) is the first listed.
NCT02558790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02558790 about?
NCT02558790 is a clinical study titled "L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD". This study is a 12-week, open-label pilot study to test the effects of MMFS-201-301 on cognition and function in adults with ADHD. Subjects may enter the trial on a stable dose of medication for ADHD, and MMFS-201-301 will be given. Subjects who do not enter on a stable dose of ADHD medication will ...
What is the current status of trial NCT02558790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-03. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02558790?
The interventions under investigation include: L-Threonic Acid Magnesium Salt (L-TAMS) (DRUG).
Who is sponsoring clinical trial NCT02558790?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.